WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Times
July 18, 2024
8:00 AM PST
11:00 AM EST
3:00 PM GMT
Overview
Join Dr. Andrew Lewis, Chief Scientific Officer, and Dr. Stuart Mair, Chief Medical Officer, in our upcoming webinar as we explore the latest developments in orally delivered GLP-1 agonists and take a look at potential future innovations.
Our expert speakers will examine obesity as a global health issue, discussing its profound impact on healthcare. They will guide us through the discovery of GLP-1 agonists as potential treatments for type 2 diabetes; the incredible potential for these therapeutics outside diabetes and explore the challenges and potential solutions for orally products. The webinar will highlight Quotient Sciences’ Translational Pharmaceutics® platform and describe how it has enabled the accelerated development of both orally delivered peptides and small molecules in the incretin family.
This engaging session will cover:
– Drivers for oral incretin analogues
– CMC and clinical challenges in their development
– Future innovation
We will be taking questions ahead of the webinar so please submit directly to events@quotientsciences.com
Don’t miss this opportunity to stay at the forefront of treatment advancements in this quickly evolving category.
Total Page Views: 326
